A Sampling of Highlights from the Literature

What We're Reading| April 02 2024 A Sampling of Highlights from the Literature: Article Recommendations from Our Deputy and Senior Editors Author 12 (4): 381. https://doi.org/10.1158/2326-6066.CIR-12-4-WWR Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Harnessing a cutaneous T-cell lymphoma mutation enhances efficacy of T-cell therapy (from Nephron via Wikimedia Commons). The efficacy of adoptive T-cell therapy is often limited by poor in vivo persistence and function. Hypothesizing that mutations underlying human T-cell cancers might suggest ways to improve the fitness of therapeutic T cells, Garcia et al. screened the effects of 71 such mutations on in vitro and in vivo T-cell phenotypes. A CARD11–PIK3R3 gene fusion was one of the mutations identified for further analysis. CARD11–PIK3R3 expression in human and mouse chimeric-antigen receptor (CAR) T cells and T-cell receptor (TCR) T cells improves their therapeutic efficacy in preclinical models without signs of malignant transformation, highlighting the potential of this approach to identify ways to improve the efficacy of adoptive T-cell therapy. Garcia J, ..., Choi J. Nature 2024 February 7;626,626–634. SMARCAL1 is a dual regulator of tumor immune evasion (Emilian Robert... You do not currently have access to this content.